Efficacy of AposTherapy® in Knee OA

• ClinicalTrials.gov Identifier: NCT03153956
• Recruitment Status: Active, not recruiting
• First Posted: May 15, 2017
• Last Update Posted: May 16, 2019
• Sponsor: NYU Langone Health
• Information provided by (Responsible Party): NYU Langone Health

Study Description

Brief Summary:

A prospective, interventional, randomized, double-arm clinical evaluation study to examine the efficacy of AposTherapy® versus a control group, in the short-term at 6 months and in the long-term at 12 months post-treatment, with the primary efficacy assessment based on improvement in knee pain score and improvement in function in patients following diagnosis of knee osteoarthritis (OA).

Condition or disease	Intervention/treatment	Phase
Osteoarthritis, Knee	Device: Calibrated AposTherapy®; Device: Non-Calibrated Sham Apos Therapy Device	Not Applicable

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 92 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment

Intervention Model Description

Phase I - A prospective, interventional, randomized, double-arm clinical evaluation of patients who have been diagnosed with OA of the knee. The active treatment arm (personally calibrated biomechanical device) will be compared to a control arm (sham-placebo device) (similar shoes without biomechanical elements).

Phase II - Open-label, cross-over study design. After the completion of phase one patients will be un-blinded to their group allocation. Patients that were allocated to the sham-placebo control group will cross to the active group and will receive the AposTherapy treatment. Patients that were allocated to the active group will continue with treatment.

• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Prospective, Randomized Double-Armed Efficacy Evaluation of AposTherapy® for the Treatment of Knee Osteoarthritis
• Actual Study Start Date: April 16, 2015
• Actual Primary Completion Date: December 7, 2018
• Estimated Study Completion Date: December 7, 2019

Arms and Interventions

Arm	Intervention/treatment
Experimental: Active Treatment Arm; Personally calibrated bio-mechanical device	Device: Calibrated AposTherapy®; a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology.
Placebo Comparator: Control Arm; sham-placebo device (similar shoes without bio-mechanical elements).	Device: Non-Calibrated Sham Apos Therapy Device; The comparator group will receive a non-calibrated sham device.

Outcome Measures

Primary Outcome Measures :

1. Western Ontario and McMaster University (WOMAC) score to 6 months post treatment [ Time Frame: 6 Months ]
   WOMAC evaluates the condition of patients with osteoarthritis of the knee and hip, including pain, stiffness, and physical functioning of the joints.

Secondary Outcome Measures :

1. Visual Analog Score (VAS) score [ Time Frame: 12 Months ]
   The visual analogue scale or visual analog scale (VAS) is a psychometric response scale which can be used in questionnaires. It is a measurement instrument for subjective characteristics or attitudes that cannot be directly measured.
2. Short-Form 36 (SF-36) score [ Time Frame: 6 Months ]
   The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health at pre-treatment and following 3 months and 6 months post-treatment.

Eligibility Criteria

• Ages Eligible for Study: 45 Years to 75 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Patients suffering from symptomatic unilateral or bilateral knee OA at the medial compartment for at least six months;
• Fulfilling the ACR clinical criteria;
• Having radiographically assessed OA of the knee with a Kellgren-Lawrence grade more than or equal to grade 2; and,
• Having VAS-Pain ≥ 3, on a scale between 0-10.
• Patients who have a shoe size between US 4 and US 12

Exclusion Criteria:

• Patients suffering from acute septic arthritis.
• Patients who received a corticosteroid injection within 3 months of the study.
• Patients who received hyaluronic acid (HA) injections within 6 months of the study
• Patients suffering from avascular necrosis of the knee.
• Patients with a history of knee buckling or recent knee injury.
• Patients who have had a joint replacement or other major surgery to the knee, hip or ankle (ipsilateral or contralateral side).
• Patients suffering from neuropathic arthropathy.
• Patients with an increased tendency to fall.
• Patients exhibiting a lack of physical or mental ability to perform or comply with the study procedure.
• Patients with a history of pathological osteoporotic fracture.
• Patients suffering from symptomatic degenerative arthritis in lower limb joints other than the knees.
• Patients with referred pain in the knees from primary back or hip joint pain.
• Patients with neurological deficits to the lower extremity (ex. foot drop)
• Patients whose shoe size is less than US 4 and greater than US 12
• Patients who have had arthroscopy within 6 months of the study
• Patients with inflammatory arthropathy

Contacts and Locations

Locations

United States, New York

New York University School of Medicine

New York, New York, United States, 10016

Sponsors and Collaborators

NYU Langone Health

Investigators

• Principal Investigator: Dennis Cardone, DO; NYU Langone Health

More Information

• Responsible Party: NYU Langone Health
• ClinicalTrials.gov Identifier: NCT03153956
• Other Study ID Numbers: 14-02127
• First Posted: May 15, 2017
• Last Update Posted: May 16, 2019
• Last Verified: May 2019

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: Yes

Keywords provided by NYU Langone Health:

AposTherapy® System; Osteoarthritis; Total knee arthroplasties; Degenerative joint disease

Additional relevant MeSH terms:

Osteoarthritis; Osteoarthritis, Knee; Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases